CURRENT STATUS OF ALL CLAIMS

Claims 1-44 (canceled)

45. (currently amended) A method of inhibiting binding of a natural ligand to a vitronectin receptor comprising contacting said vitronectin receptor with a peptide containing the sequence Arg-Gly-Asp, said Arg-Gly-Asp sequence being conformationally restricted, thereby selectively inhibiting binding of said natural ligand to said vitronectin receptor ~~with respect to the function of other receptors~~.

46. (previously presented) The method of claim 45, wherein said inhibition occurs *in vivo*.

47. (previously presented) A method of selectively inhibiting attachment of cells to vitronectin comprising providing to said cells *in vitro* a solution of a peptide containing the sequence Arg-Gly-Asp, said Arg-Gly-Asp sequence being conformationally restricted, thereby selectively inhibiting attachment of said cells to said vitronectin.

48. (previously presented) A method of selectively inhibiting attachment of cells to vitronectin comprising providing to said cells *in vivo* a solution of a peptide containing the sequence Arg-Gly-Asp, said Arg-Gly-Asp sequence being conformationally restricted, thereby selectively inhibiting attachment of said cells to said vitronectin.

49. (previously presented) A method of selectively inhibiting binding of vitronectin receptor-containing cells to a substrate comprising providing to said cells *in vitro* a solution containing a peptide that encompasses the sequence Arg-Gly-Asp, said Arg-Gly-Asp sequence being conformationally restricted, thereby selectively inhibiting binding of said vitronectin receptor-containing cells to said substrate.

50. (previously presented) A method of selectively inhibiting binding of vitronectin receptor-containing cells to a substrate comprising providing to said cells *in vivo* a solution containing a peptide that encompasses the sequence Arg-Gly-Asp, said Arg-Gly-Asp sequence being conformationally restricted, thereby selectively inhibiting binding of said vitronectin receptor-containing cells to said substrate.

51. (previously presented) A method of selectively inhibiting binding of vitronectin receptor-containing cells to a substrate comprising the steps of:

a. providing to said cells *in vitro* a peptide containing the sequence Arg-Gly-Asp in solution, said Arg-Gly-Asp sequence being conformationally restricted; and

b. contacting said cells with said solution.

52. (previously presented) A method of selectively inhibiting binding of vitronectin receptor-containing cells to a substrate comprising the steps of:

a. providing to said cells *in vivo* a peptide containing the sequence Arg-Gly-Asp in solution, said Arg-Gly-Asp sequence being conformationally restricted; and

b. contacting said cells with said solution.

53. (previously presented) A method of selectively inhibiting binding of cells to a substrate comprising providing to said cells *in vitro* a solution of a peptide containing an Arg-Gly-Asp sequence chemically modified with an additional chemical structure, wherein said additional chemical structure conformationally restricts the stereochemical structure of said Arg-Gly-Asp sequence in such a way that the affinity of the Arg-Gly-Asp binding site sequence for a particular receptor is enhanced.

54. (previously presented) A method of selectively inhibiting binding of cells to a substrate comprising providing to said cells *in vivo* a solution of a peptide containing an Arg-Gly-Asp sequence chemically modified with an additional chemical structure, wherein said additional chemical structure conformationally restricts the stereochemical structure of said Arg-Gly-Asp sequence in such a way that the affinity of the Arg-Gly-Asp binding site sequence for a particular receptor is enhanced.

55. (New) The method of claim 45, wherein said peptide is a cyclic peptide.

56. (New) The method of claim 47, wherein said peptide is a cyclic peptide.

57. (New) The method of claim 48, wherein said peptide is a cyclic peptide.

58. (New) The method of claim 49, wherein said peptide is a cyclic peptide.

59. (New) The method of claim 50, wherein said peptide is a cyclic peptide.

60. (New) The method of claim 51, wherein said peptide is a cyclic peptide.

61. (New) The method of claim 52, wherein said peptide is a cyclic peptide.